Advanced Search

 

Study ID Status Title Patient Level Data
HPR20001 Terminated Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/ritonavir Compared to Open-label Current PI therapy in HIV-1 infected, Protease Inhibitor Experienced Adults for 2 weeks with Long-term Assessment (>48 weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
HPV-Meta-analysis-201110 Completed Integrated Safety Summary of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix®)
HS2100275 Completed An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients Study Listed on ClinicalStudyDataRequest.com
HS2101951 Completed Clinical Evaluation of Valaciclovir Hydrochloride: 256U87 in Patients with Chickenpox - Open Uncontrolled Study.
HS210914 Completed An open-label, single-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children. Study Listed on ClinicalStudyDataRequest.com
HSP108233 Terminated A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK625433 in Healthy Subjects and in Subjects who are Chronically Infected with Hepatitis C.
HSV Meta analyses Completed Meta analyses on pregnancy outcomes with respect to the effect of Herpes Simplex Virus (HSV) antigen and of the adjuvant (AS04)
HTP103265 Completed An open label, non-randomized positron emission tomography study in healthy male subjects to investigate brain 5-HT1A receptor occupancy, pharmacokinetics and safety of single oral doses of GSK163090, using the ligand [11C]-WAY100635.
HTP110333 Completed A randomized, single-blind, placebo-controlled, 2 part study to evaluate the safety and tolerability of GSK163090 at single and repeat doses in subjects with MDD
HYT104152 Completed A Phase I Study to Characterize the Pharmacokinetics of Topotecan at 4 mg/m2 Administered Weekly as a 30-Minute Intravenous Infusion in Patients with Cancer
HYT105962 Completed A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients with Brain Metastases from Non-Small Cell Lung Cancer
HYT109091 Completed A Phase I Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Two Schedules of Oral Topotecan in combination with Pazopanib in Subjects with Advanced Solid Tumors
HZA102928 Completed A randomised, double blind, placebo controlled, parallel group, 14 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled GW685698X containing magnesium stearate in healthy subjects Study Listed on ClinicalStudyDataRequest.com
HZA102940 Completed A randomised, double-blind, placebo-controlled, four-way crossover study to compare the pharmacodynamics and pharmacokinetics of GW685698X and GW642444M when administered separately and in combination as a single dose from a novel dry powder device in healthy japanese subjects Study Listed on ClinicalStudyDataRequest.com
HZA105871 Completed A randomised, double-blind, placebo-controlled, four-way crossover study to compare the pharmacodynamics and pharmacokinetics of GW685698X and GW642444M when administered separately and in combination as a single dose from a novel dry powder device in healthy subjects Study Listed on ClinicalStudyDataRequest.com
HZA108799 Completed A double-blind, placebo-controlled, crossover study to investigate the safety, tolerability and pharmacokinetics of single dose dry powder GW685698X containing magnesium stearate in subjects with mild to moderate asthmatic patients Study Listed on ClinicalStudyDataRequest.com
HZA109895 Terminated An exploratory study to evaluate the response of salmeterol plus fluticasone vs fluticasone alone to experimental nasal inoculation with rhinovirus Study Listed on ClinicalStudyDataRequest.com
HZA109912 Completed A 12-week, randomised, double-blind, placebo-controlled, three-period, cross-over pilot study comparing the effect of salmeterol/fluticasone propionate, fluticasone propionate and placebo on perpheral blood eosinophils and serum IL-5 in response to allergen challenge in asthma subjects when allergen challenge is administered at 1 hour or 11-12 hours post-dose of the dosing interval Study Listed on ClinicalStudyDataRequest.com
HZC111348 Completed Study HZC111348, a repeat-dose study of GW685698/GW642444 Inhalation Powder versus Placebo in the Treatment of Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
I13105054 Completed A dose-escalating study of the safety and pharmacokinetics of GSK679586A in healthy volunteers and mild asthmatics.
IBN104125 Completed A multi centre, randomised, open label, cross-over study to evaluate the percentage of false negative osteoporosis diagnosis’s using the standard case-finding procedure as described by the Dutch Institute for Healthcare (CBO) and to determine the preference of adult osteoporosis patients between once monthly dosing of ibandronate (150 mg) and once weekly dosing of alendronate (70 mg)
IDB-200-001 Completed A Randomized, Double-Blind Trial Evaluating the Safety and Immunogenicity of an Influenza Vaccine with reduced Preservative (FluLaval™ TR) and a Standard Influenza Vaccine (Fluarix®) in subjects between 18-60 and Over 60 Years of Age. Study Listed on ClinicalStudyDataRequest.com
IGZ111452 Terminated A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1247303 in Healthy Male and Female Subjects
ILI105618 Completed A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 (SB-485232) Administered by Intravenous Infusion in Combinationwith Rituximab in Adult Patients with B Cell Non-Hodgkin'sLymphoma" Study Listed on ClinicalStudyDataRequest.com
ILI108621 Completed A phase I, dose escalation study to assess the safety & biological activity of Interleukin 18 (SB-485232) administered by IV infusion in combination with pegylated liposomal doxorubicin (Doxil) in advanced stage epithelial ovarian cancer Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.